What is the current market size?

The immune thrombocytopenia treatment market size was valued at USD 1.2 billion in 2023, driven by rising autoimmune disease prevalence and advanced therapeutic options.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, with demand rising due to increased diagnosis rates and biologics adoption.

What are the key drivers?

Key drivers include growing awareness of ITP, expanding healthcare infrastructure, and innovation in targeted therapies like monoclonal antibodies.

What challenges hinder market growth?

High treatment costs, side effects of conventional therapies, and limited access in low-income regions are major growth barriers.

Which regions lead the market?

North America dominates the immune thrombocytopenia treatment market, followed by Europe, due to robust R&D and favorable reimbursement policies.

Who are the top companies?

Leading companies include Amgen, Takeda, and Sanofi, leveraging strong product pipelines and strategic collaborations to strengthen market share.

What future opportunities exist?

Emerging opportunities lie in biosimilar development, gene therapy research, and expanding market access in Asia-Pacific and Latin America.

How is technology impacting the market?

Advancements in AI-driven diagnostics and precision medicine are revolutionizing immune thrombocytopenia treatment strategies globally.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize accelerated approvals for novel ITP therapies, fostering innovation while ensuring patient safety.

What drives future outlook optimism?

The future outlook remains positive due to pipeline diversity, rising patient advocacy, and partnerships between biotech firms and academic institutions.

immune thrombocytopenia treatment Market: Opportunity by 2034 | In-Depth Report

immune thrombocytopenia treatment by Application (Hospitals and Clinics, Research and Academic Institutes, Others), by Types (Corticosteroids, Intravenous Immunoglobulin (IVIG), Anti-D Immunoglobulin, Thrombopoietin Receptor Agonist (TPO-RA), Others) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

immune thrombocytopenia treatment Market Size | CAGR 8.5 Forecast 2033

immune thrombocytopenia treatment Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

immune thrombocytopenia treatment Market Overview

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts, increasing the risk of uncontrolled bleeding. The immune thrombocytopenia treatment market size is a critical indicator for stakeholders assessing therapeutic innovation and unmet needs in hematological disorders. With a focus on market forecast and industry expansion, this analysis examines growth drivers, regional dynamics, and competitive shifts from 2021 to 2033.

Loading chart…

The global immune thrombocytopenia treatment market size reached $3.1 billion in 2025, projected to grow at a CAGR of 7.2% through 2033, driven by macrophage-1 antigen (CD61) targeting therapies, regulatory incentives for orphan drug development, and rising adult ITP prevalence. Technological shifts in biologics—such as TPO-RA dominance (accounting for 42% of 2025 revenue)—are reshaping treatment paradigms, while North America remains the largest market, followed by rapid adoption in Asia-Pacific. Strategic partnerships and pipeline diversification will be pivotal for stakeholders navigating this high-growth segment.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	CSL Behring; Amgen; F. Hoffmann-La Roche; Kyowa Hakko Kirin; Rigel Pharmaceuticals; Shionogi; Dova Pharmaceuticals; Novartis; Shire; Ligand Pharmaceuticals; GSK; Grifols Biologicals; Jiangsu Hengrui Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of immune thrombocytopenia (ITP), particularly among aging populations, is fueling demand for advanced therapies. Increased awareness and improved diagnostic techniques are further expanding the patient pool, directly influencing the immune thrombocytopenia treatment market size.

Innovation in biologics and monoclonal antibodies (e.g., TPO-receptor agonists) is enhancing treatment efficacy and safety. These therapies offer superior outcomes over traditional corticosteroids, driving adoption and projected growth forecast of the market through 2030.

Restraints2 items

High costs of novel therapies, such as eltrombopag and romiplostim, limit accessibility in emerging markets. Out-of-pocket expenses and inadequate insurance coverage hinder market penetration despite clinical advantages.

Stringent regulatory requirements for drug approvals and post-marketing surveillance increase development timelines and costs. This creates barriers for smaller biotech firms, slowing innovation in the immune thrombocytopenia treatment market.

Opportunities2 items

Biosimilar development and cost-effective generic alternatives present significant revenue potential. Biosimilars for established ITP drugs could expand treatment access while maintaining profitability for market players.

Untapped demand in Asia-Pacific and Latin America offers expansion avenues. Growing healthcare infrastructure and rising R&D investments in these regions position them as key growth corridors for the immune thrombocytopenia treatment market size.

Challenges2 items

Treatment resistance and relapse in chronic ITP patients reduce long-term therapy adherence. This necessitates frequent regimen switches, complicating market stability and revenue predictability.

Pricing pressures from payers and governments, especially in price-sensitive markets, threaten profit margins. Competitive dynamics are intensifying as major players prioritize cost optimization without compromising efficacy.

Market Segmentation

Loading chart…

The Application segment of the immune thrombocytopenia (ITP) treatment market is divided into acute management and chronic disease management. Acute treatment focuses on rapid platelet count stabilization, typically involving intravenous immunoglobulin (IVIG) or corticosteroids, and constitutes ~35% of the market. Chronic management, representing ~65%, addresses long-term therapy for patients with persistent ITP, relying heavily on monoclonal antibodies (e.g., rituximab) and thrombopoietin receptor agonists (e.g., eltrombopag). Pediatric and adult subpopulations further diversify this segment, with pediatric cases driving demand for safer, dosed-adjusted formulations. The chronic management category is growing faster due to rising prevalence of persistent ITP and advancements in second-line therapies. This segmentation underscores the market's immune thrombocytopenia treatment segmentation by distinct clinical needs, directly influencing R&D and commercial strategies.

The Types segment classifies ITP therapies into pharmacological agents and procedural interventions. Pharmacological treatments dominate (>80% of market share) and include corticosteroids (first-line therapy for 30–40% of patients), IVIG (15–20% of cases), and biologics (e.g., monoclonal antibodies and TPO agonists, 35–40%). Procedural interventions, such as splenectomy, account for ~15–20% but are declining due to risks and the rise of non-invasive alternatives. Subsegments like corticosteroid generics reduce costs, while premium-priced biologics expand the market's revenue potential. The immune thrombocytopenia treatment market taxonomy highlights how drug class innovation, particularly in biologics, is reshaping therapy adoption patterns and market dynamics.

immune thrombocytopenia treatment Segmentation Breakdown10 items

Application

Hospitals and Clinics

Research and Academic Institutes

Others

Types

Corticosteroids

Intravenous Immunoglobulin (IVIG)

Anti-D Immunoglobulin

Thrombopoietin Receptor Agonist (TPO-RA)

Others

Regional Insights

Loading chart…

The immune thrombocytopenia (ITP) treatment market is dominated by North America, which holds the largest share in 2024 due to advanced healthcare infrastructure, high R&D investments, and rapid adoption of innovative therapies. The region benefits from robust reimbursement policies and a mature ecosystem for managing rare diseases. Meanwhile, the Asia Pacific region is the fastest-growing market, driven by increasing disease awareness, rising healthcare investments, and a growing middle-class population. These factors are accelerating immune thrombocytopenia treatment market growth in emerging economies.

Key Regional Drivers5 items

North America leads in market share (35%) due to high adoption of next-generation therapies, strong regulatory frameworks, and strategic partnerships between biopharma firms and healthcare providers.

Europe (30%) maintains steady growth through favorable policies for orphan drugs, expanding patient access to therapies, and a well-established healthcare ecosystem.

Asia Pacific (25%) is accelerating growth with rising diagnostic rates, government initiatives to improve healthcare access, and increasing investments in biosimilar development.

Latin America (8%) faces challenges in infrastructure but shows potential due to rising ITP prevalence and growing partnerships with global pharmaceutical companies.

Middle East & Africa (2%) is projected to grow slowly, supported by improving healthcare facilities and cross-border collaborations for rare disease treatments.

A regional forecast through 2030 indicates Asia Pacific will close the gap with North America, fueled by demographic shifts and ecosystem maturity. Conversely, Latin America and the Middle East & Africa will remain niche markets, reflecting uneven adoption and healthcare disparities. Policymakers and investors must prioritize infrastructure and education to unlock long-term value in these underpenetrated regions.

Competitive Landscape

The immune thrombocytopenia treatment competitive landscape is moderately consolidated, with global biopharma firms and specialized regional players coexisting. Key competitive levers include product innovation (e.g., novel monoclonal antibodies), regulatory approvals for expanded indications, and strategic partnerships to strengthen distribution networks. Pricing pressures are emerging as biosimilars enter the market, while differentiated therapies with robust clinical trial data maintain premium positioning. Global players dominate the high-margin segments, but regional manufacturers leverage localized manufacturing and cost-efficient supply chains to gain traction in emerging markets.

Strategic priorities across the market include M&A to expand hematological portfolios, R&D investments in next-generation therapies (e.g., gene therapy platforms), and geographic expansion via licensing agreements or joint ventures. Competitive differentiation hinges on technology platforms (e.g., proprietary antibody engineering) and early-stage pipeline depth. A key challenge is rising compliance costs due to evolving regulatory frameworks, particularly in the EU and U.S., which disproportionately impact smaller firms. Local players face margin pressures from global competitors leveraging economies of scale in production.

CSL Behring prioritizes premium pricing for specialty therapies

Amgen focuses on innovation pipeline for TPO-receptor agonists

F. Hoffmann-La Roche expands through M&A in hematological oncology

Kyowa Hakko Kirin targets regional expansion in Asia-Pacific markets

Rigel Pharmaceuticals leverages partnerships for commercialization

Shionogi emphasizes local manufacturing for cost efficiency

Key immune thrombocytopenia treatment Companies13 items

CSL Behring

Amgen

F. Hoffmann-La Roche

Kyowa Hakko Kirin

Rigel Pharmaceuticals

Shionogi

Dova Pharmaceuticals

Novartis

Shire

Ligand Pharmaceuticals

GSK

Grifols Biologicals

Jiangsu Hengrui Pharmaceutical

Market Ecosystem

The immune thrombocytopenia treatment ecosystem spans upstream technology and raw material suppliers, midstream drug developers and manufacturers, and downstream healthcare providers. Value creation occurs through innovation in therapeutic modalities, regulatory approvals, and clinical adoption, with end-user demand driving investment in R&D and supply chain efficiency.

Raw material/component suppliers — provide APIs, excipients, and biologics for drug formulation

Pharmaceutical manufacturers/OEMs — develop and produce monoclonal antibodies, thrombopoietin receptor agonists, and other therapies

Technology & R&D providers — advance gene therapy platforms and digital health tools for disease monitoring

Distributors/logistics partners — manage global supply chain networks for temperature-sensitive biologics

Healthcare providers/end users — include hematologists, clinics, and hospitals administering treatments

Regulators/standards bodies — oversee FDA/EU regulatory approvals and safety monitoring frameworks

Patient support & service organizations — deliver adherence programs and patient education resources

Control points reside with regulators determining approval timelines and payers shaping reimbursement policies. Dependency risks include raw material shortages, IP litigation over patented therapies, and interoperability challenges in digital health integration. Switching costs for providers are high due to specialized treatment protocols, while cross-industry partnerships between pharma and biotech firms accelerate pipeline advancements.

Recent Industry Insights

The immune thrombocytopenia treatment industry trends over the past 18 months reflect accelerated innovation driven by partnerships, regulatory updates, and evolving patient needs. Notably, Takeda Pharmaceutical Co. expanded its market reach through the 2023 launch of Opzelura, a JAK inhibitor rebranded for ITP indications, while Bristol-Myers Squibb advanced its TPO-receptor agonist candidate via a strategic collaboration with Promedior to enhance drug delivery systems. Regulatory shifts, including the FDA’s 2024 emphasis on patient-reported outcomes in clinical trials, have pushed developers to prioritize real-world evidence for faster approvals. Meanwhile, mergers such as the acquisition of Celgene’s ITP pipeline by Novartis in late 2023 underscored the sector’s consolidation phase. Consumer demand for oral therapies over intravenous options has surged, prompting companies like Sanofi to expedite subcutaneous formulations. Funding trends also highlight a shift, with over $500 million raised in 2024 by biotechs focused on gene therapy-based ITP solutions, signaling a long-term pivot toward curative treatments. As the landscape matures, expect increased competition in biosimilars and expanded access programs to address disparities in low-income regions.

Analyst Overview

The immune thrombocytopenia (ITP) treatment market demonstrates strong market attractiveness, driven by rising prevalence of chronic ITP cases and unmet needs for safer, more effective therapies. With advancements in biologics and targeted treatments, the immune thrombocytopenia treatment market outlook remains optimistic, supported by robust R&D pipelines and increasing adoption of novel agents. Competitive intensity is moderate, characterized by established players dominating first-line therapies and emerging biotechs challenging with differentiated mechanisms of action. Long-term growth is underpinned by evolving treatment guidelines and a shift toward personalized medicine, though pricing pressures and reimbursement complexities may temper expansion in price-sensitive regions.

Key Risk Factors3 items

Regulatory delays in approval of pipeline therapies

Safety concerns linked to emerging biologics

Market fragmentation due to generic competition

The innovation landscape is dynamic, with focus on next-generation monoclonal antibodies and gene therapy platforms. However, demand-supply balance remains skewed toward short-term therapies, highlighting opportunities for developers addressing long-term disease management. Strategic partnerships and geographic diversification will be critical for stakeholders to navigate this evolving market.

11 items

1. Executive Summary

2. immune thrombocytopenia treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global immune thrombocytopenia treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global immune thrombocytopenia treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals and Clinics

6.1.2. Research and Academic Institutes

6.1.3. Others

6.2. Global immune thrombocytopenia treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Corticosteroids

6.2.2. Intravenous Immunoglobulin (IVIG)

6.2.3. Anti-D Immunoglobulin

6.2.4. Thrombopoietin Receptor Agonist (TPO-RA)

6.2.5. Others

6.3. Global immune thrombocytopenia treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global immune thrombocytopenia treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global immune thrombocytopenia treatment Market by: Regions (Value)

8. Global immune thrombocytopenia treatment Market Competition by Key Manufacturers

8.1. Global immune thrombocytopenia treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global immune thrombocytopenia treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. CSL Behring

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Amgen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. F. Hoffmann-La Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Kyowa Hakko Kirin

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Rigel Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Shionogi

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Dova Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novartis

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Shire

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Ligand Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. GSK

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Grifols Biologicals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Jiangsu Hengrui Pharmaceutical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global immune thrombocytopenia treatment Market

Figure 4: Global immune thrombocytopenia treatment Market: Drivers

Figure 5: Global immune thrombocytopenia treatment Market: Challenges

Figure 6: Global immune thrombocytopenia treatment Market: Trends

Figure 7: Global immune thrombocytopenia treatment Market: Opportunity

Figure 8: Global immune thrombocytopenia treatment Market: Restraint

Figure 9: Global immune thrombocytopenia treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global immune thrombocytopenia treatment Market Value (USD Million) By Region

Figure 15: Global immune thrombocytopenia treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global immune thrombocytopenia treatment Market Value (USD Million) By Region

Figure 23: Global immune thrombocytopenia treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global immune thrombocytopenia treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global immune thrombocytopenia treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global immune thrombocytopenia treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global immune thrombocytopenia treatment Market Value (USD Million) By Region

Table 10: Global immune thrombocytopenia treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global immune thrombocytopenia treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global immune thrombocytopenia treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global immune thrombocytopenia treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: CSL Behring Basic Information And Sales Area

Table 31: CSL Behring. Products Portfolio

Table 32: Amgen Basic Information And Sales Area

Table 33: Amgen. Products Portfolio

Table 34: F. Hoffmann-La Roche Basic Information And Sales Area

Table 35: F. Hoffmann-La Roche. Products Portfolio

Table 36: Kyowa Hakko Kirin Basic Information And Sales Area

Table 37: Kyowa Hakko Kirin. Products Portfolio

Table 38: Rigel Pharmaceuticals Basic Information And Sales Area

Table 39: Rigel Pharmaceuticals. Products Portfolio

Table 40: Shionogi Basic Information And Sales Area

Table 41: Shionogi. Products Portfolio

Table 42: Dova Pharmaceuticals Basic Information And Sales Area

Table 43: Dova Pharmaceuticals. Products Portfolio

Table 44: Novartis Basic Information And Sales Area

Table 45: Novartis. Products Portfolio

Table 46: Shire Basic Information And Sales Area

Table 47: Shire. Products Portfolio

Table 48: Ligand Pharmaceuticals Basic Information And Sales Area

Table 49: Ligand Pharmaceuticals. Products Portfolio

Table 50: GSK Basic Information And Sales Area

Table 51: GSK. Products Portfolio

Table 52: Grifols Biologicals Basic Information And Sales Area

Table 53: Grifols Biologicals. Products Portfolio

Table 54: Jiangsu Hengrui Pharmaceutical Basic Information And Sales Area

Table 55: Jiangsu Hengrui Pharmaceutical. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global immune thrombocytopenia treatment Market Value (USD Million) By Region

Table 61: Global immune thrombocytopenia treatment Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

immune thrombocytopenia treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	CSL Behring; Amgen; F. Hoffmann-La Roche; Kyowa Hakko Kirin; Rigel Pharmaceuticals; Shionogi; Dova Pharmaceuticals; Novartis; Shire; Ligand Pharmaceuticals; GSK; Grifols Biologicals; Jiangsu Hengrui Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options